Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics Limited has announced its Annual General Meeting scheduled for October 22, 2025, which will be held both in person and virtually. The meeting will cover the consideration of the 2025 Annual Financial Report and a non-binding resolution to adopt the 2025 Remuneration Report. This meeting is significant for stakeholders as it provides insights into the company’s financial health and governance practices, although the resolutions are advisory and non-binding.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited operates in the pharmaceutical industry, focusing on therapeutic solutions. The company is engaged in the development and commercialization of innovative treatments, aiming to address unmet medical needs within its market focus.
Average Trading Volume: 4,290,184
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.